Background and Purpose-The prevalence of atrial fibrillation increases with age, but age-specific data on the incidence of stroke and death in anticoagulated patients with atrial fibrillation are more limited, particularly with regard to comparisons of relative risks of clinical outcomes between the different age strata in relation to quality of anticoagulation control among warfarin users. Methods-We investigated the incidence of adverse outcomes between tertiles of age groups (age, <67 [n=722] 
T he prevalence of atrial fibrillation (AF) increases with age 1 and is a major cause of stroke and death among the older patients. Oral anticoagulation with the vitamin K antagonists (VKAs; eg, warfarin) reduces the risk of ischemic stroke and all-cause mortality, 2 and the net clinical benefit of warfarin increases with age. 3 However, the absolute risk of bleeding during antithrombotic therapy also increases with age, which confers management challenges among the elderly, including anticoagulation monitoring and drug compliance, as well as the existence of comorbidities. 4 Consequently, elderly patients with AF are often not prescribed anticoagulation or are unable to maintain warfarin therapy use over time, thus resulting in such patients being exposed to a high risk of fatal and disabling strokes. 5 Nonetheless, age-specific data on the incidence and risk factors of stroke and death in anticoagulated patients with nonvalvular AF are less evident. Some insights from real-world observational cohorts are available, 6 but clinical trial data have had relatively low proportions of elderly subjects (aged >75 years), apart from the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) trial, 7 which specifically investigated stroke prevention in patients with AF aged >75 years and the Warfarin Versus Aspirin for Stroke Prevention in Octogenarians With Atrial Fibrillation (WASPO) trial investigated in octogenarians. 8 To investigate the efficacy and safety outcomes in an elderly anticoagulated AF cohort, we performed a post hoc analysis from the Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS) trial, 9 which was a multicentre, randomized, open-label noninferiority study with blinded assessment of outcome that compared fixed-dose idraparinux with conventional anticoagulation by dose-adjusted oral VKA therapy for the prevention of thromboembolism in patients with AF and an indication for long-term anticoagulation. First, we investigated the incidence of adverse outcomes (stroke/systemic embolism [ 
Methods
The design of the AMADEUS trial has previously been described. 9, 10 In brief, the AMADEUS trial was a multicentre, randomized, openlabel noninferiority study with blinded assessment of outcome that compared fixed-dose idraparinux with conventional anticoagulation by dose-adjusted oral VKA therapy for the prevention of thromboembolism in patients with AF. Eligible patients had ECG-documented nonvalvular AF and an indication for long-term anticoagulation, based on the presence of at least 1 of the following risk factors: previous ischemic stroke, transient ischemic attack or systemic embolism, hypertension requiring drug treatment, left ventricular dysfunction, age >75 years, or age 65 to 75 years with either diabetes mellitus or symptomatic coronary artery disease (CAD). Exclusion criteria included the inability to provide consent, contraindication or other requirement for anticoagulation, calculated creatinine clearance of <10 mL/min, breastfeeding, pregnancy, and recent or anticipated invasive procedures with potential for uncontrolled bleeding. We examined the population according to tertiles of age (ie, <67, 67-74, and ≥75 years). Outcomes were analyzed for the warfarin arm of the trial, as the development of idraparinux has been discontinued, and thus, the idraparinux data would be less relevant for our clinical practice.
Definitions of End Points
This post hoc analysis of the AMADEUS trial used pooled data from the VKA arm on an intention to treat basis. The primary outcome of this analysis was the composite of cardiovascular death and SSE. Stroke included ischemic, hemorrhagic, or undefined causes that resulted in a focal neurological deficit of sudden onset, with a corresponding defect on brain imaging. Systemic embolism was confirmed by angiography, surgery, or autopsy.
The principal safety outcome of the present analysis was any clinically relevant bleeding, which was defined as major bleeding or nonmajor clinically relevant bleeding. The latter was defined as overt bleeding that did not satisfy the criteria for major bleeding but that met defined criteria and included repetitive epistaxis for >5 minutes at least twice in 24 hours, hematuria (spontaneous or lasting >24 hours), hematemesis, and subcutaneous hematomas of >25 cm 2 if spontaneous or >100 cm 2 if after trauma. Major bleeding was defined as bleeding that was fatal, intracranial or affecting another critical anatomic site, overt bleeding with a drop of hemoglobin of ≥20 g/L, or requiring transfusion of ≥2 units of erythrocytes. All suspected outcome events were adjudicated by the original AMADEUS central adjudication committee who were blinded to treatment assignment.
Statistical Analysis
The characteristics of the patients are reported as percentages and mean±SD. Comparisons between tertiles of age groups (<67, 67-74, and ≥75 years) were made using Fisher exact test when comparing categorical variables and the Kruskal-Wallis test for continuous variables. Outcomes by each age group were calculated by the overall rate of adverse events per 100 patient-years. We used Cox proportional hazard models to estimate the hazard ratios (HRs) for primary outcome (adjusted for sex, previous hypertension, heart failure, coronary artery disease, diabetes mellitus, and SSE) and any clinically relevant bleeding (adjusted for sex, previous hypertension, heart failure, coronary artery disease, diabetes mellitus, creatinine, SSE, TTR, and aspirin) according to increasing age. The linear-by-linear association test was used to show a linear trend between age strata and crude outcomes. KaplanMeier curves were assessed using a Log-rank test. Correlations and regression analyses were performed between TTR and adverse outcomes (any clinically relevant bleeding or cardiovascular death/SSE events). A 2-tailed P value of <0.05 was considered statistically significant. Analyses were performed using SPSS (version 21).
Results
We studied 2293 patients with AF taking warfarin and categorized them into tertiles by age groups, that is, age <67 years (n=722; 31.5%), age 67 to 74 years (n=747; 32.6%), and age ≥75 years (n=824; 35.9%). Table 1 summarizes the characteristics of patients in relation to age. Elderly patients (age, ≥75 years) were more likely to be women and have permanent AF and a high CHA 2 DS 2 -VASc score (as expected).
The primary end point of combined cardiovascular death and SSE events occurred in 29 patients (3.8% per 100 patientsyears) in the top tertile, 20 (2.9% per 100 patients-years) in the middle tertile, and 9 (1.4% per 100 patients-years) in the lowest tertile, respectively ( Table 2 ). Cardiovascular death rates were 2.0%, 2.1%, and 0.6% per 100 patients-years, and SSE rates were 2.0%, 1.0%, and 0.8% per 100 patients-years, respectively. Kaplan-Meier curves showing the combined cardiovascular death and SSE end point in relation to age tertiles are shown in Figure 1 . As expected, there was an increase in absolute event rates with increasing age (Log-rank test, P=0.02).
Data for the principal safety end point of any clinically relevant bleeding are shown in Table 2 . Any clinically relevant bleeding occurred in 79 patients (13.3% per 100 patients-years) in the top age tertile, 85 patients (14.4% per 100 patientsyears) in the middle age tertile, and 62 patients (10.7% per 100 patients-years) in the lowest age tertile. Major bleeding occurred in 17, 7, and 5 patients (2.6%, 1.1%, and 0.8% per 100 patients-years), respectively. In the well-controlled warfarin subgroup (with TTR≥60%), any clinically relevant bleeding rates were 7.4%, 9.2%, and 8.6% per 100 patients-years, respectively, and the major bleeding rates were 1.6%, 0.6%, and 0.3% per 100 patients-years, respectively. Only 9 cases of intracranial hemorrhage (ICH) were seen in the warfarin arm, and 8 of the 9 ICH cases (89%) had TTR<60%. Of the 9 patients having ICH, events in age <67, 67 to 75, and ≥75 subgroups were 2, 2, and 3 among men and 0, 1, and 1 among women, respectively.
Adverse outcomes by age category quartiles (where the same trends are seen, but statistical power was more limited) or in the whole-cohort trial data (n=4576; with data consistent with the warfarin arm data) are shown in Tables I and II in Figure 2 shows the forest plots for the different age strata in relation to the various efficacy end points. As expected, the combined cardiovascular death and SSE end point had higher absolute rates with increasing age strata (P for trend=0.005; Table 2 ), with a 2.6-fold greater relative hazard in the top age tertile group, using the lowest tertile as a reference (adjusted HR, 2.63; 95% confidence interval, 1.23-5.63). There was a trend for higher risk with the middle age tertile (adjusted HR, 1.92; 95% confidence interval, 0.87-4.24), using the lowest tertile as a reference. Similarly, the top and middle age tertile groups had higher absolute rates for cardiovascular death (Table 2) , with 3.3-fold and 3.4-fold greater relative hazard, using the lowest tertile as a reference (adjusted HR, 3.31; 95% confidence interval, 1.08-10.1 and 3.37; 95% confidence interval, 1.11-10.2). For SSE, there were higher absolute rates with age strata ( with nonsignificance for a higher relative hazard with the top and middle age tertiles, using the lowest tertile as a reference.
Cardiovascular Death and SSE

Any Clinically Relevant Bleeding
For the end point of any clinically relevant bleeding, there were no significant differences in absolute rates with increasing age strata (P for trend=0.55). There were only nonsignificant trends for a higher relative hazards with the top (adjusted HR, 1.20 [0.80-1.80]) and middle (adjusted HR, 1.39 [0.97-1.98]) age tertiles, using the lowest tertile as a reference (Figure 3) . Similar findings were seen in the subgroup of patients taking warfarin with TTR≥60% (P for trend=0.60).
Impact of Age and Sex
In our study, men were younger than women (mean age: men, 69±9 years versus women, 72±8 years; P<0.001), but there was no difference in the event rates for the primary outcome and any clinically relevant bleeding between men and women (primary outcome: men, 2.7% versus women, 2.9% per 100 patient-years; P=not significant and any clinically relevant bleeding: men, 11.6% versus women, 10.9% per 100 patient-years; P=not significant). Also, we found no interaction of sex and age with adverse outcomes, such as the primary outcome (P interaction=0.41) and any clinically relevant bleeding (P interaction=0.11).
Correlations and Multivariate Analyses
Correlation and regression analyses between TTR and adverse outcomes (any clinically relevant bleeding or cardiovascular death/SSE events) are shown in Figure 4 . TTR was significantly negatively correlated with any clinically relevant bleeding (r=−0.91; P<0.001) and cardiovascular death/SSE rates (r=−0.76; P=0.01).
On multivariate Cox regression analysis, age ≥75 years (P=0.002), previous CAD (P=0.007), and stroke (P<0.0001) emerged as the main predictors of combined cardiovascular death and SSE end point. Previous CAD (P=0.01), aspirin use (P=0.001), and warfarin control with TTR<60% (P<0.001) were the significant independent predictors of any clinically relevant bleeding.
Discussion
In this study, the high risk of cardiovascular death and SSE was evident among anticoagulated patients with AF, and this increased with increasing age. Second, elderly patients with AF had favorable outcomes for any clinically relevant bleeding irrespective of age strata. However, TTR was significantly negatively correlated with both any clinically relevant bleeding and cardiovascular death/SSE rates. Third, the main independent predictors of the combined cardiovascular death and SSE end point were age, previous CAD, and stroke, whereas independent predictors of any clinically relevant bleeding were previous CAD, aspirin use, and poor TTR. 
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Elderly patients with AF carry a high risk of cardiovascular death and SSE. In the meta-analysis of AF investigators, stroke and vascular events increased with increasing age. 11 However, as the patients with AF got older, the beneficial reduction in stroke and vascular events with warfarin relatively increased, whereas the (small) effect of aspirin declined even more as patients got older.
11 Indeed, the highest risk patients derive the greatest net clinical benefit when balancing ischemic stroke reduction against serious bleeding when warfarin is used properly, and this could be even greater if the non-VKA oral anticoagulants were used. 12, 13 There was no significant difference in any clinically relevant bleeding between the age strata, and there was no statistically significant increase in HRs with increasing age strata.
When the quality of anticoagulation control with warfarin (as reflected by TTR≥60%) was considered, the same trend was observed between the age strata. Indeed, good quality control as reflected by the average TTR is associated with the lowest stroke and bleeding event rates.
14,15 Indeed, we found that TTR was significantly correlated with any clinically relevant bleeding and cardiovascular death/SSE rates, emphasizing the importance of good quality anticoagulation control. 15 Thus, effective stroke prevention in various guidelines with oral anticoagulants refers to the use of well-controlled warfarin (TTR≥70%) or non-VKA oral anticoagulants. 16, 17 A recent European Society of Cardiology position article 16 also recommended the use of new SAMe-TT 2 R 2 (sex female, age <60 years, medical history [more than two comorbidities], treatment [interacting drugs], tobacco use [doubled], race [doubled]) score to help decision making by identifying patients with AF expected to do well on warfarin (SAMe-TT 2 R 2 score, 0-1) or those likely to have poor anticoagulation control (SAMe-TT 2 R 2 score, >2). 18, 19 Nonetheless, being elderly also requires additional attention in terms of impaired cognitive function 20 and frailty. The positive effect of oral anticoagulation use on stroke was evident even in the highest age strata of the Loire Valley AF cohort. 6 Indeed, this study, based on a clinical trial cohort, is in agreement with the Loire Valley AF cohort 6 and the principal results from the BAFTA trial. 7 Also, the present analyses complement these previous studies by adjudicated trial cohort data for adverse outcomes (ie, cardiovascular death and stroke), as well as bleeding outcomes (any clinically relevant bleeding) associated with warfarin intensity.
Unsurprisingly, age, previous CAD, and stroke were independent predictors of cardiovascular death and SSE in our cohort. Data on the elderly from the Danish nationwide cohort study clearly show how age ≥75 years represents a particularly high-risk patient group for recurrent stroke/thromboembolism. 21 Of note, previous CAD, aspirin use, and poor TTR control also emerged as independent predictors for any clinically relevant bleeding among anticoagulated patients with AF.
Limitations
These results are based on a post hoc analysis of the AMADEUS trial and should be interpreted as hypothesis generating. The AMADEUS population was at relatively low risk of both ischemic stroke and bleeding events compared with real-world patients and may have some limited statistical power for subgroup comparisons. Indeed, we had limited power to investigate the relationship between TTR and ICH, given the low number of events (n=9) and short follow-up period, although 8 of the 9 ICH cases (89%) had TTR<60%. However, it is worth emphasizing that elderly anticoagulated patients with AF have a low risk of ICH. 22 Also, no significant sex differences in anticoagulation-related major bleeding are evident. 23 Despite comparable or greater comorbidities, elderly women (aged ≥75 years) had similar rates of anticoagulationrelated major bleeding compared with younger women (aged <75 years), arguing for anticoagulation of all age groups. This is despite women having a longer life span (and its associated age-related comorbidities), suggesting that oral anticoagulants at an older age is still relevant and physicians should not shy A B Figure 3 . Hazard ratios for any clinically relevant bleeding in overall warfarin group and well-controlled warfarin group (time in therapeutic range [TTR]≥60%) according to increasing age (adjusted for sex, previous hypertension, heart failure, coronary artery disease, diabetes mellitus, stroke/systemic embolism, TTR, and aspirin). away from it. We were unable to find supportive evidence that identified a relationship between age and incidence of ICH among the male population, and further studies are necessary.
Nonetheless, we cannot exclude residual confounding in the comparison between the aged-group categories, although multivariable adjustment was performed to take account of baseline imbalance. In particular, women were under-represented in our study, in common with most cardiovascular trials. Although we found no interaction of sex and age with adverse outcomes, the interactions of age and sex are possible in any post hoc or subgroup analysis. Finally, relatively few of the extreme elderly (eg, aged >85 years; 1.7%) were included in this randomized controlled trial cohort. Therefore, these results may not necessarily reflect the real-world clinical scenario of elderly patients with AF.
In conclusion, elderly patients with AF have a higher risk of cardiovascular death and SSE, but any clinical relevant bleeding risks are not significantly different irrespective of increasing age strata. Good quality anticoagulation control (as reflected by high TTRs) is significantly negatively correlated with any clinically relevant bleeding and cardiovascular death/SSE rates, clearly emphasizing the importance of good quality anticoagulation control, especially among elderly patients with AF.
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